Stoneridge Investment Partners LLC held its position in TG Therapeutics Inc. (NASDAQ:TGTX) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 295,482 shares of the biopharmaceutical company’s stock at the end of the second quarter. Stoneridge Investment Partners LLC’s holdings in TG Therapeutics were worth $1,791,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the stock. BlackRock Group LTD increased its position in TG Therapeutics by 152.8% in the first quarter. BlackRock Group LTD now owns 17,443 shares of the biopharmaceutical company’s stock worth $149,000 after buying an additional 10,542 shares in the last quarter. State Street Corp increased its position in TG Therapeutics by 3.4% in the first quarter. State Street Corp now owns 1,181,038 shares of the biopharmaceutical company’s stock worth $10,064,000 after buying an additional 39,117 shares in the last quarter. UBS Asset Management Americas Inc. increased its position in TG Therapeutics by 30.0% in the first quarter. UBS Asset Management Americas Inc. now owns 2,021,310 shares of the biopharmaceutical company’s stock worth $17,223,000 after buying an additional 466,193 shares in the last quarter. Geode Capital Management LLC increased its position in TG Therapeutics by 10.1% in the first quarter. Geode Capital Management LLC now owns 277,119 shares of the biopharmaceutical company’s stock worth $2,361,000 after buying an additional 25,517 shares in the last quarter. Finally, Mariner Wealth Advisors LLC increased its position in TG Therapeutics by 1.4% in the first quarter. Mariner Wealth Advisors LLC now owns 18,286 shares of the biopharmaceutical company’s stock worth $156,000 after buying an additional 255 shares in the last quarter. Hedge funds and other institutional investors own 54.66% of the company’s stock.

TG Therapeutics Inc. (NASDAQ:TGTX) traded down 0.78% during mid-day trading on Thursday, reaching $7.66. The company had a trading volume of 241,050 shares. The stock’s market capitalization is $417.13 million. TG Therapeutics Inc. has a one year low of $5.41 and a one year high of $14.87. The company’s 50-day moving average is $6.49 and its 200-day moving average is $7.44.

TG Therapeutics (NASDAQ:TGTX) last posted its quarterly earnings results on Monday, August 8th. The biopharmaceutical company reported ($0.33) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.29) by $0.04. TG Therapeutics had a negative return on equity of 58.77% and a negative net margin of 40,142.11%. Equities research analysts anticipate that TG Therapeutics Inc. will post ($1.22) earnings per share for the current year.

TGTX has been the subject of a number of analyst reports. SunTrust Banks Inc. initiated coverage on TG Therapeutics in a research note on Friday, May 27th. They issued a “buy” rating and a $18.00 price target for the company. Brean Capital restated a “buy” rating on shares of TG Therapeutics in a research note on Tuesday, May 31st. Roth Capital restated a “buy” rating and issued a $33.00 price target on shares of TG Therapeutics in a research note on Thursday, June 9th. FBR & Co restated a “buy” rating on shares of TG Therapeutics in a research note on Monday, June 13th. Finally, Zacks Investment Research downgraded TG Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, July 14th. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the company. TG Therapeutics currently has a consensus rating of “Buy” and an average price target of $20.81.

TG Therapeutics Company Profile

TG Therapeutics, Inc (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for b-cell malignancies and autoimmune diseases. The Company is developing over two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the CD20 antigen found on mature B-lymphocytes.

5 Day Chart for NASDAQ:TGTX

Want to see what other hedge funds are holding TGTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for TG Therapeutics Inc. (NASDAQ:TGTX).

Receive News & Ratings for TG Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.